Cargando…

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma

We previously showed that the proteasome inhibitor carfilzomib and the histone deacetylase inhibitor (HDACI) vorinostat cooperated to induce cell apoptosis in one T-cell leukemia cell line in vitro, implying the possibility of the combination treatment of carfilzomib and vorinostat as a potential th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Minjie, Chen, Gege, Wang, Houcai, Xie, Bingqian, Hu, Liangning, Kong, Yuanyuan, Yang, Guang, Tao, Yi, Han, Ying, Wu, Xiaosong, Zhang, Yiwen, Dai, Bojie, Shi, Jumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045381/ https://www.ncbi.nlm.nih.gov/pubmed/27074555 http://dx.doi.org/10.18632/oncotarget.8667

Ejemplares similares

Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells
por: Kong, Yuanyuan, et al.
Publicado: (2016)

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma
por: Gao, Minjie, et al.
Publicado: (2017)

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3
por: Wang, Houcai, et al.
Publicado: (2016)

Pterostilbene Induces Cell Apoptosis and Cell Cycle Arrest in T-Cell Leukemia/Lymphoma by Suppressing the ERK1/2 Pathway
por: Chang, Gaomei, et al.
Publicado: (2017)

TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma
por: Tao, Yi, et al.
Publicado: (2017)

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I
por: Yang, Guang, et al.
Publicado: (2015)

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
por: Gao, Lu, et al.
Publicado: (2015)

Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma
por: Kong, Yuanyuan, et al.
Publicado: (2019)

DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway
por: Sun, Xi, et al.
Publicado: (2017)

Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo
por: Xie, Bingqian, et al.
Publicado: (2016)

DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2
por: Kong, Yuanyuan, et al.
Publicado: (2019)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
por: Chao, Min-Wu, et al.
Publicado: (2015)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe
por: Hu, Liangning, et al.
Publicado: (2020)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway
por: Lu, Kang, et al.
Publicado: (2020)

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
por: Sato, Akinori
Publicado: (2012)

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia
por: van Tilburg, Cornelis M., et al.
Publicado: (2019)

Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues
por: Bieszczad, Bartosz, et al.
Publicado: (2021)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Multiple myeloma cancer stem cells
por: Gao, Minjie, et al.
Publicado: (2016)

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
por: Duvic, M, et al.
Publicado: (2006)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
por: Petruccelli, Luca A., et al.
Publicado: (2011)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
por: Jeitany, Maya, et al.
Publicado: (2020)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Targeting the autophagy in bone marrow stromal cells overcomes resistance to vorinostat in chronic lymphocytic leukemia
por: Ding, Lu, et al.
Publicado: (2018)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
por: Lautz, Timothy B., et al.
Publicado: (2012)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy
por: Young, Christine S., et al.
Publicado: (2017)

Down-Regulation of 11β-Hydroxysteroid Dehydrogenase Type 2 by Bortezomib Sensitizes Jurkat Leukemia T Cells against Glucocorticoid-Induced Apoptosis
por: Tao, Yi, et al.
Publicado: (2013)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Cheung, Laurence C., et al.
Publicado: (2021)

Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest
por: Yang, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0mu431sc3ohebaj1dl071mrgt0